Current status and unanswered questions on the use of Denosumab in giant cell tumor of bone

Denosumab is a monoclonal antibody to RANK ligand approved for use in giant cell tumour (GCT) of bone. Due to its efficacy, Denosumab is recommended as the first option in inoperable or metastatic GCT. Denosumab has also been used pre-operatively to downstage tumours with large soft tissue extension...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Clin Sarcoma Res
Main Authors: Gaston, Czar Louie, Grimer, Robert J., Parry, Michael, Stacchiotti, Silvia, Dei Tos, Angelo Paolo, Gelderblom, Hans, Ferrari, Stefano, Baldi, Giacomo G., Jones, Robin L., Chawla, Sant, Casali, Paolo, LeCesne, Axel, Blay, Jean-Yves, Dijkstra, Sander P. D., Thomas, David M., Rutkowski, Piotr
פורמט: Artigo
שפה:Inglês
יצא לאור: BioMed Central 2016
נושאים:
Review
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC5022265/
https://ncbi.nlm.nih.gov/pubmed/27651889
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13569-016-0056-0
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים